Moreover, in patients with CKD G3a–G5 not on dialysis and with levels of intact PTH progressively rising or persistently above the upper normal limit for the assay, they recommend that PTH level ought to be evaluated for modifiable factors, including hyperphosphatemia, hypocalcaemia, high phosphate intake, and vitamin D deficiency (2C). This evidence concerns the gene PTH and hyperphosphatemia.